Twenty years of GPCR structures: 2000 - 2020
Note: This is a historical table with data from August 2000 to March 2020. The table is not being updated with more recent structures.
Show only one entry per receptor
Show all entries
Hold down the shift key to sort by multiple columns
Row | PDB ID | Family | Receptor | Organism | Res. (Ang.) | Putative State | Ligand | Ligand chemical class |
Ligand pharmacological class |
Signaling partner | Antibody | Fusion protein | Method | Year | References |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 4JKV | Frizzled | Smoothened | Human | 2.45 | inactive | LY2940680 | small molecule | antagonist | NA | NA | BRIL-NT | X-RAY | 2013 | Wang et al. 2013 |
2 | 4N4W | Frizzled | Smoothened | Human | 2.8 | inactive | SANT-1 | small molecule | antagonist | NA | NA | BRIL-NT | X-RAY | 2014 | Wang et al. 2014 |
3 | 4O9R | Frizzled | Smoothened | Human | 3.2 | inactive | Cyclopamine | small molecule | antagonist | NA | NA | BRIL-NT | X-RAY | 2014 | Weierstall et al. 2014 |
4 | 4QIM | Frizzled | Smoothened | Human | 2.61 | inactive | ANTA XV | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2014 | Wang et al. 2014 |
5 | 4QIN | Frizzled | Smoothened | Human | 2.6 | inactive or minimally activated | SAG1.5 | small molecule | agonist | NA | NA | BRIL-IL3 | X-RAY | 2014 | Wang et al. 2014 |
6 | 5L7D | Frizzled | Smoothened | Human | 3.2 | inactive or minimally activated | Cholesterol | small molecule | agonist (allosteric, bound to extracellular CRD) | NA | NA | BRIL-IL3 | X-RAY | 2016 | Byrne et al. 2016 |
7 | 5L7I | Frizzled | Smoothened | Human | 3.3 | inactive | Vismodegib | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Byrne et al. 2016 |
8 | 4K5Y | Secretin | CRF1 corticotropin-releasing factor receptor | Human | 2.98 | inactive | CP-376395 | small molecule | antagonist (negative allosteric modulator) | NA | NA | NA | X-RAY | 2013 | Hollenstein et al. 2013 |
9 | 4L6R | Secretin | Glucagon receptor | Human | 3.3 | inactive | Unliganded | NA | NA | NA | NA | BRIL-NT | X-RAY | 2013 | Siu et al. 2013 |
10 | 4Z9G | Secretin | CRF1 corticotropin-releasing factor receptor | Human | 3.18 | inactive | CP-376395 | small molecule | antagonist (allosteric) | NA | NA | T4L-IL2 | X-RAY | 2016 | Dore et al. 2016 |
11 | 5EE7 | Secretin | Glucagon receptor | Human | 2.5 | inactive | MK-0893 | small molecule | antagonist (allosteric) | NA | NA | T4L-IL2 | X-RAY | 2016 | Jazayeri et al. 2016 |
12 | 1F88 | Rhodopsin | Rhodopsin | Bovine | 2.8 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2000 | Palczewski et al. 2000 |
13 | 1GZM | Rhodopsin | Rhodopsin | Bovine | 2.65 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2003 | Li et al. 2003 |
14 | 1HZX | Rhodopsin | Rhodopsin | Bovine | 2.8 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2001 | Teller et al. 2001 |
15 | 1L9H | Rhodopsin | Rhodopsin | Bovine | 2.6 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2002 | Okada et al. 2002 |
16 | 1U19 | Rhodopsin | Rhodopsin | Bovine | 2.2 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2004 | Okada et al. 2004 |
17 | 2G87 | Rhodopsin | Rhodopsin | Bovine | 2.6 | inactive or minimally activated (bathorhodopsin) | All-trans-retinal | small molecule | agonist | NA | NA | NA | X-RAY | 2006 | Nakamichi et al. 2006 |
18 | 2HPY | Rhodopsin | Rhodopsin | Bovine | 2.8 | inactive or minimally activated (lumirhodopsin) | All-trans-retinal | small molecule | agonist | NA | NA | NA | X-RAY | 2006 | Nakamichi et al. 2006 |
19 | 2I35 | Rhodopsin | Rhodopsin | Bovine | 3.8 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2006 | Salom et al. 2006 |
20 | 2I36 | Rhodopsin | Rhodopsin | Bovine | 4.1 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2006 | Salom et al. 2006 |
21 | 2I37 | Rhodopsin | Rhodopsin | Bovine | 4.15 | inactive or minimally activated (early photoactivation intermediate) | All-trans-retinal | small molecule | agonist | NA | NA | NA | X-RAY | 2006 | Salom et al. 2006 |
22 | 2J4Y | Rhodopsin | Rhodopsin | Bovine | 3.4 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2007 | Standfuss et al. 2007 |
23 | 2PED | Rhodopsin | Rhodopsin | Bovine | 2.95 | inactive | 9-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2007 | Nakamichi et al. 2007 |
24 | 2R4R | Rhodopsin | Beta2 adrenergic receptor | Human | 3.4 | inactive | Carazolol | small molecule | inverse agonist | NA | Fab (intracellular) | NA | X-RAY | 2007 | Rasmussen et al. 2007 |
25 | 2R4S | Rhodopsin | Beta2 adrenergic receptor | Human | 3.4 | inactive | Carazolol | small molecule | inverse agonist | NA | Fab (intracellular) | NA | X-RAY | 2007 | Rasmussen et al. 2007 |
26 | 2RH1 | Rhodopsin | Beta2 adrenergic receptor | Human | 2.4 | inactive | Carazolol | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2007 | Cherezov et al. 2007 |
27 | 2VT4 | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.7 | inactive | Cyanopindolol | small molecule | antagonist | NA | NA | NA | X-RAY | 2008 | Warne et al. 2008 |
28 | 2X72 | Rhodopsin | Rhodopsin | Bovine | 3.0 | activated | All-trans-retinal | small molecule | agonist | Gt peptide (fused) | NA | NA | X-RAY | 2011 | Standfuss et al. 2011 |
29 | 2Y00 | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.5 | inactive or minimally activated | Dobutamine | small molecule | partial agonist | NA | NA | NA | X-RAY | 2011 | Warne et al. 2011 |
30 | 2Y01 | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.6 | inactive or minimally activated | Dobutamine | small molecule | partial agonist | NA | NA | NA | X-RAY | 2011 | Warne et al. 2011 |
31 | 2Y02 | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.6 | inactive or minimally activated | Carmoterol | small molecule | agonist | NA | NA | NA | X-RAY | 2011 | Warne et al. 2011 |
32 | 2Y03 | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.85 | inactive or minimally activated | Isoprenaline | small molecule | agonist | NA | NA | NA | X-RAY | 2011 | Warne et al. 2011 |
33 | 2Y04 | Rhodopsin | Beta1 adrenergic receptor | Turkey | 3.05 | inactive or minimally activated | Salbutamol | small molecule | partial agonist | NA | NA | NA | X-RAY | 2011 | Warne et al. 2011 |
34 | 2YCW | Rhodopsin | Beta1 adrenergic receptor | Turkey | 3.0 | inactive | Carazolol | small molecule | antagonist | NA | NA | NA | X-RAY | 2011 | Moukhametzianov et al. 2011 |
35 | 2YCX | Rhodopsin | Beta1 adrenergic receptor | Turkey | 3.25 | inactive | Cyanopindolol | small molecule | antagonist | NA | NA | NA | X-RAY | 2011 | Moukhametzianov et al. 2011 |
36 | 2YCY | Rhodopsin | Beta1 adrenergic receptor | Turkey | 3.15 | inactive | Cyanopindolol | small molecule | antagonist | NA | NA | NA | X-RAY | 2011 | Moukhametzianov et al. 2011 |
37 | 2YCZ | Rhodopsin | Beta1 adrenergic receptor | Turkey | 3.65 | inactive | Iodocyanopindolol | small molecule | antagonist | NA | NA | NA | X-RAY | 2011 | Moukhametzianov et al. 2011 |
38 | 2YDO | Rhodopsin | A2A adenosine receptor | Human | 3.0 | inactive or minimally activated | Adenosine | small molecule | agonist | NA | NA | NA | X-RAY | 2011 | Lebon et al. 2011 |
39 | 2YDV | Rhodopsin | A2A adenosine receptor | Human | 2.6 | inactive or minimally activated | NECA | small molecule | agonist | NA | NA | NA | X-RAY | 2011 | Lebon et al. 2011 |
40 | 2Z73 | Rhodopsin | Rhodopsin | Squid | 2.5 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2008 | Murakami et al. 2008 |
41 | 2ZIY | Rhodopsin | Rhodopsin | Squid | 3.7 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2008 | Shimamura et al. 2008 |
42 | 3AYM | Rhodopsin | Rhodopsin | Squid | 2.8 | inactive or minimally activated (bathorhodopsin) | All-trans-retinal | small molecule | agonist | NA | NA | NA | X-RAY | 2011 | Murakami et al. 2011 |
43 | 3AYN | Rhodopsin | Rhodopsin | Squid | 2.7 | inactive | 9-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2011 | Murakami et al. 2011 |
44 | 3C9L | Rhodopsin | Rhodopsin | Bovine | 2.65 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2008 | Stenkamp et al. 2008 |
45 | 3C9M | Rhodopsin | Rhodopsin | Bovine | 3.4 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2008 | Stenkamp et al. 2008 |
46 | 3CAP | Rhodopsin | Rhodopsin | Bovine | 2.9 | activated | Unliganded | NA | NA | NA | NA | NA | X-RAY | 2008 | Park et al. 2008 |
47 | 3D4S | Rhodopsin | Beta2 adrenergic receptor | Human | 2.8 | inactive | Timolol | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2008 | Hanson et al. 2008 |
48 | 3DQB | Rhodopsin | Rhodopsin | Bovine | 3.2 | activated | Unliganded | NA | NA | Gt peptide (fused) | NA | NA | X-RAY | 2008 | Scheerer et al. 2008 |
49 | 3EML | Rhodopsin | A2A adenosine receptor | Human | 2.6 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2008 | Jaakola et al. 2008 |
50 | 3KJ6 | Rhodopsin | Beta2 adrenergic receptor | Human | 3.4 | inactive | Carazolol | small molecule | inverse agonist | NA | Fab (intracellular) | NA | X-RAY | 2010 | Bokoch et al. 2010 |
51 | 3NY8 | Rhodopsin | Beta2 adrenergic receptor | Human | 2.84 | inactive | ICI 118551 | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2010 | Wacker et al. 2010 |
52 | 3NY9 | Rhodopsin | Beta2 adrenergic receptor | Human | 2.84 | inactive | Comp. 2 | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2010 | Wacker et al. 2010 |
53 | 3NYA | Rhodopsin | Beta2 adrenergic receptor | Human | 3.16 | inactive | Alprenolol | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2010 | Wacker et al. 2010 |
54 | 3OAX | Rhodopsin | Rhodopsin | Bovine | 2.6 | inactive | 11-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2011 | Makino et al. 2011 |
55 | 3ODU | Rhodopsin | CXCR4 chemokine receptor | Human | 2.5 | inactive | IT1t | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2010 | Wu et al. 2010 |
56 | 3OE0 | Rhodopsin | CXCR4 chemokine receptor | Human | 2.9 | inactive | CVX15 | peptide | antagonist | NA | NA | T4L-IL3 | X-RAY | 2010 | Wu et al. 2010 |
57 | 3OE6 | Rhodopsin | CXCR4 chemokine receptor | Human | 3.2 | inactive | IT1t | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2010 | Wu et al. 2010 |
58 | 3OE8 | Rhodopsin | CXCR4 chemokine receptor | Human | 3.1 | inactive | IT1t | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2010 | Wu et al. 2010 |
59 | 3OE9 | Rhodopsin | CXCR4 chemokine receptor | Human | 3.1 | inactive | IT1t | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2010 | Wu et al. 2010 |
60 | 3P0G | Rhodopsin | Beta2 adrenergic receptor | Human | 3.5 | activated | BI-167107 | small molecule | agonist | NA | Nanobody (intracellular) | T4L-NT | X-RAY | 2011 | Rasmussen et al. 2011 |
61 | 3PBL | Rhodopsin | D3 dopamine receptor | Human | 2.89 | inactive | Eticlopride | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2010 | Chien et al. 2010 |
62 | 3PDS | Rhodopsin | Beta2 adrenergic receptor | Human | 3.5 | inactive or minimally activated | FAUC50 | small molecule | agonist (irreversible) | NA | NA | T4L-IL3 | X-RAY | 2011 | Rosenbaum et al. 2011 |
63 | 3PQR | Rhodopsin | Rhodopsin | Bovine | 2.85 | activated | All-trans-retinal | small molecule | agonist | Gt peptide (fused) | NA | NA | X-RAY | 2011 | Choe et al. 2011 |
64 | 3PWH | Rhodopsin | A2A adenosine receptor | Human | 3.3 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | NA | X-RAY | 2011 | Dore et al. 2011 |
65 | 3PXO | Rhodopsin | Rhodopsin | Bovine | 3.0 | activated | All-trans-retinal | small molecule | agonist | NA | NA | NA | X-RAY | 2011 | Choe et al. 2011 |
66 | 3QAK | Rhodopsin | A2A adenosine receptor | Human | 2.71 | inactive or minimally activated | UK432097 | small molecule | agonist | NA | NA | T4L-IL3 | X-RAY | 2011 | Xu et al. 2011 |
67 | 3REY | Rhodopsin | A2A adenosine receptor | Human | 3.31 | inactive | XAC | small molecule | antagonist | NA | NA | NA | X-RAY | 2011 | Dore et al. 2011 |
68 | 3RFM | Rhodopsin | A2A adenosine receptor | Human | 3.6 | inactive | Caffeine | small molecule | antagonist | NA | NA | NA | X-RAY | 2011 | Dore et al. 2011 |
69 | 3RZE | Rhodopsin | H1 histamine receptor | Human | 3.1 | inactive | Doxepin | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2011 | Shimamura et al. 2011 |
70 | 3UZA | Rhodopsin | A2A adenosine receptor | Human | 3.27 | inactive | Comp. 4g | small molecule | antagonist | NA | NA | NA | X-RAY | 2012 | Congreve et al. 2012 |
71 | 3UZC | Rhodopsin | A2A adenosine receptor | Human | 3.34 | inactive | Comp. 4g | small molecule | antagonist | NA | NA | NA | X-RAY | 2012 | Congreve et al. 2012 |
72 | 3V2W | Rhodopsin | S1P1 sphingosine 1-phosphate receptor | Human | 3.35 | inactive | ML056 | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2012 | Hanson et al. 2012 |
73 | 3V2Y | Rhodopsin | S1P1 sphingosine 1-phosphate receptor | Human | 2.8 | inactive | ML056 | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2012 | Hanson et al. 2012 |
74 | 3VG9 | Rhodopsin | A2A adenosine receptor | Human | 2.7 | inactive | ZM-241385 | small molecule | antagonist | NA | Fab (intracellular, allosteric inverse agonist) | NA | X-RAY | 2012 | Hino et al. 2012 |
75 | 3VGA | Rhodopsin | A2A adenosine receptor | Human | 3.1 | inactive | ZM-241385 | small molecule | antagonist | NA | Fab (intracellular, allosteric inverse agonist) | NA | X-RAY | 2012 | Hino et al. 2012 |
76 | 3VW7 | Rhodopsin | PAR1 proteinase-activated receptor | Human | 2.2 | inactive | Vorapaxar | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2012 | Zhang et al. 2012 |
77 | 3ZEV | Rhodopsin | NTS1 neurotensin receptor | Rat | 3.0 | inactive or minimally activated | Neurotensin (8-13) | peptide | agonist | NA | NA | NA | X-RAY | 2014 | Egloff et al. 2014 |
78 | 3ZPQ | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.8 | inactive | 4-(Piperazin-1-yl)-1H-indole | small molecule | antagonist | NA | NA | NA | X-RAY | 2013 | Christopher et al. 2013 |
79 | 3ZPR | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.7 | inactive | 4-Methyl-2-(piperazin-1-yl)quinoline | small molecule | antagonist | NA | NA | NA | X-RAY | 2013 | Christopher et al. 2013 |
80 | 4A4M | Rhodopsin | Rhodopsin | Bovine | 3.3 | activated | All-trans-retinal | small molecule | agonist | NA | NA | NA | X-RAY | 2012 | Deupi et al. 2012 |
81 | 4AMI | Rhodopsin | Beta1 adrenergic receptor | Turkey | 3.2 | inactive or minimally activated | Bucindolol | small molecule | agonist (biased, beta-arrestin) | NA | NA | NA | X-RAY | 2012 | Warne et al. 2012 |
82 | 4AMJ | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.3 | inactive or minimally activated | Carvedilol | small molecule | agonist (biased, beta-arrestin) | NA | NA | NA | X-RAY | 2012 | Warne et al. 2012 |
83 | 4BEY | Rhodopsin | Rhodopsin | Bovine | 2.9 | activated | Unliganded | NA | NA | Gt peptide (fused) | NA | NA | X-RAY | 2013 | Singhal et al. 2013 |
84 | 4BEZ | Rhodopsin | Rhodopsin | Bovine | 3.3 | activated | Unliganded | NA | NA | NA | NA | NA | X-RAY | 2013 | Singhal et al. 2013 |
85 | 4BUO | Rhodopsin | NTS1 neurotensin receptor | Rat | 2.75 | inactive or minimally activated | Neurotensin (8-13) | peptide | agonist | NA | NA | NA | X-RAY | 2014 | Egloff et al. 2014 |
86 | 4BV0 | Rhodopsin | NTS1 neurotensin receptor | Rat | 3.1 | inactive or minimally activated | Neurotensin (8-13) | peptide | agonist | NA | NA | NA | X-RAY | 2014 | Egloff et al. 2014 |
87 | 4BVN | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.1 | inactive | Cyanopindolol | small molecule | antagonist | NA | NA | NA | X-RAY | 2014 | Miller-Gallacher et al. 2014 |
88 | 4BWB | Rhodopsin | NTS1 neurotensin receptor | Rat | 3.57 | inactive or minimally activated | Neurotensin (8-13) | peptide | agonist | NA | NA | NA | X-RAY | 2014 | Egloff et al. 2014 |
89 | 4DAJ | Rhodopsin | M3 muscarinic receptor | Rat | 3.4 | inactive | Tiotropium | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2012 | Kruse et al. 2012 |
90 | 4DJH | Rhodopsin | Kappa opioid receptor | Human | 2.9 | inactive | JDTic | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2012 | Wu et al. 2012 |
91 | 4DKL | Rhodopsin | Mu opioid receptor | Mouse | 2.8 | inactive | Funaltrexamine | small molecule | antagonist (irreversible) | NA | NA | T4L-IL3 | X-RAY | 2012 | Manglik et al. 2012 |
92 | 4EA3 | Rhodopsin | NOP nociceptin-orphanin FQ receptor | Human | 3.01 | inactive | Peptide mimetic c-24 | small molecule | antagonist | NA | NA | BRIL-NT | X-RAY | 2012 | Thompson et al. 2012 |
93 | 4EIY | Rhodopsin | A2A adenosine receptor | Human | 1.8 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2012 | Liu et al. 2012 |
94 | 4EJ4 | Rhodopsin | Delta opioid receptor | Mouse | 3.4 | inactive | Naltrindole | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2012 | Granier et al. 2012 |
95 | 4GBR | Rhodopsin | Beta2 adrenergic receptor | Human | 3.99 | inactive | Carazolol | small molecule | inverse agonist | NA | NA | T4L-NT | X-RAY | 2012 | Zou et al. 2012 |
96 | 4GPO | Rhodopsin | Beta1 adrenergic receptor | Turkey | 3.5 | inactive | Unliganded | NA | NA | NA | NA | NA | X-RAY | 2013 | Huang et al. 2013 |
97 | 4GRV | Rhodopsin | NTS1 neurotensin receptor | Rat | 2.8 | activated (partially) | Neurotensin (8-13) | peptide | agonist | NA | NA | T4L-IL3 | X-RAY | 2012 | White et al. 2012 |
98 | 4IAQ | Rhodopsin | 5-HT1B serotonin receptor | Human | 2.8 | inactive or minimally activated | Dihydroergotamine | small molecule | agonist | NA | NA | BRIL-IL3 | X-RAY | 2013 | Wang et al. 2013 |
99 | 4IAR | Rhodopsin | 5-HT1B serotonin receptor | Human | 2.7 | inactive or minimally activated | Ergotamine | small molecule | agonist | NA | NA | BRIL-IL3 | X-RAY | 2013 | Wang et al. 2013 |
100 | 4IB4 | Rhodopsin | 5-HT2B serotonin receptor | Human | 2.7 | inactive or minimally activated | Ergotamine | small molecule | agonist (biased, beta-arrestin) | NA | NA | BRIL-IL3 | X-RAY | 2013 | Wacker et al. 2013 |
101 | 4J4Q | Rhodopsin | Rhodopsin | Bovine | 2.65 | activated | Beta-octylglucoside | small molecule | NA | Gt peptide (fused) | NA | NA | X-RAY | 2013 | Park et al. 2013 |
102 | 4LDE | Rhodopsin | Beta2 adrenergic receptor | Human | 2.79 | activated | BI-167107 | small molecule | agonist | NA | Nanobody (intracellular) | T4L-NT | X-RAY | 2013 | Ring et al. 2013 |
103 | 4LDL | Rhodopsin | Beta2 adrenergic receptor | Human | 3.1 | activated | Hydroxybenzylisoproterenol | small molecule | agonist | NA | Nanobody (intracellular) | T4L-NT | X-RAY | 2013 | Ring et al. 2013 |
104 | 4LDO | Rhodopsin | Beta2 adrenergic receptor | Human | 3.2 | activated | Adrenaline | small molecule | agonist | NA | Nanobody (intracellular) | T4L-NT | X-RAY | 2013 | Ring et al. 2013 |
105 | 4MBS | Rhodopsin | CCR5 chemokine receptor | Human | 2.71 | inactive | Maraviroc | small molecule | inverse agonist | NA | NA | Rubredoxin-IL3 | X-RAY | 2013 | Tan et al. 2013 |
106 | 4MQS | Rhodopsin | M2 muscarinic receptor | Human | 3.5 | activated | Iperoxo | small molecule | agonist | NA | Nanobody (intracellular) | NA | X-RAY | 2013 | Kruse et al. 2013 |
107 | 4MQT | Rhodopsin | M2 muscarinic receptor | Human | 3.7 | activated | Iperoxo + LY2119620 | small molecule | agonist + positive allosteric modulator | NA | Nanobody (intracellular) | NA | X-RAY | 2013 | Kruse et al. 2013 |
108 | 4N6H | Rhodopsin | Delta opioid receptor | Human | 1.8 | inactive | Naltrindole | small molecule | antagonist | NA | NA | BRIL-NT | X-RAY | 2013 | Fenalti et al. 2013 |
109 | 4NC3 | Rhodopsin | 5-HT2B serotonin receptor | Human | 2.8 | inactive or minimally activated | Ergotamine | small molecule | agonist (biased, beta-arrestin) | NA | NA | BRIL-IL3 | X-RAY | 2013 | Liu et al. 2013 |
110 | 4NTJ | Rhodopsin | P2Y12 receptor | Human | 2.62 | inactive | AZD1283 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2014 | Zhang et al. 2014 |
111 | 4PHU | Rhodopsin | FFA1 receptor (GPR40) | Human | 2.33 | inactive | TAK-875 or fasiglifam | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2014 | Srivastava et al. 2014 |
112 | 4PXF | Rhodopsin | Rhodopsin | Bovine | 2.75 | activated | Unliganded | NA | NA | Visual arrestin-1 peptide | NA | NA | X-RAY | 2014 | Szczepek et al. 2014 |
113 | 4PXZ | Rhodopsin | P2Y12 receptor | Human | 2.5 | inactive or minimally activated | 2-MeSADP | small molecule | agonist | NA | NA | BRIL-IL3 | X-RAY | 2014 | Zhang et al. 2014 |
114 | 4PY0 | Rhodopsin | P2Y12 receptor | Human | 3.1 | inactive or minimally activated | 2-MeSADP | small molecule | agonist | NA | NA | BRIL-IL3 | X-RAY | 2014 | Zhang et al. 2014 |
115 | 4QKX | Rhodopsin | Beta2 adrenergic receptor | Human | 3.3 | activated | Covalently-bound analog of noradrenaline | small molecule | agonist (irreversible) | NA | Nanobody (intracellular) | T4L-NT | X-RAY | 2014 | Weichert et al. 2014 |
116 | 4RWA | Rhodopsin | Delta opioid receptor | Human | 3.28 | inactive | H-Dmt-Tic-Phe-Phe-NH2 (DIPP-NH2) | peptide | antagonist | NA | NA | BRIL-NT | X-RAY | 2015 | Fenalti et al. 2015 |
117 | 4RWD | Rhodopsin | Delta opioid receptor | Human | 2.7 | inactive | H-Dmt-Tic-Phe-Phe-NH2 (DIPP-NH2) | peptide | antagonist | NA | NA | BRIL-NT | X-RAY | 2015 | Fenalti et al. 2015 |
118 | 4RWS | Rhodopsin | CXCR4 chemokine receptor | Human | 3.1 | inactive | Viral chemokine | peptide | antagonist | NA | NA | T4L-IL3 | X-RAY | 2015 | Qin et al. 2015 |
119 | 4S0V | Rhodopsin | OX2 orexin receptor | Human | 2.5 | inactive | Suvorexant | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2015 | Yin et al. 2015 |
120 | 4U14 | Rhodopsin | M3 muscarinic receptor | Rat | 3.57 | inactive | Tiotropium | small molecule | inverse agonist | NA | NA | dsT4L-IL3 | X-RAY | 2014 | Thorsen et al. 2014 |
121 | 4U15 | Rhodopsin | M3 muscarinic receptor | Rat | 2.8 | inactive | Tiotropium | small molecule | inverse agonist | NA | NA | dsT4L-IL3 | X-RAY | 2014 | Thorsen et al. 2014 |
122 | 4U16 | Rhodopsin | M3 muscarinic receptor | Rat | 3.7 | inactive | N-methyl scopolamine | small molecule | antagonist | NA | NA | dsT4L-IL3 | X-RAY | 2014 | Thorsen et al. 2014 |
123 | 4UG2 | Rhodopsin | A2A adenosine receptor | Human | 2.6 | inactive or minimally activated | CGS21680 | small molecule | agonist | NA | NA | NA | X-RAY | 2015 | Lebon et al. 2015 |
124 | 4UHR | Rhodopsin | A2A adenosine receptor | Human | 2.6 | inactive or minimally activated | CGS21680 | small molecule | agonist | NA | NA | NA | X-RAY | 2015 | Lebon et al. 2015 |
125 | 4WW3 | Rhodopsin | Rhodopsin | Squid | 2.8 | inactive or minimally activated (lumirhodopsin) | All-trans-retinal | small molecule | agonist | NA | NA | NA | X-RAY | 2015 | Murakami et al. 2015 |
126 | 4X1H | Rhodopsin | Rhodopsin | Bovine | 2.29 | activated | Unliganded | NA | NA | NA | NA | NA | X-RAY | 2015 | Blankenship et al. 2015 |
127 | 4XEE | Rhodopsin | NTS1 neurotensin receptor | Rat | 2.9 | activated (partially) | Neurotensin (8-13) | peptide | agonist | NA | NA | T4L-IL3 | X-RAY | 2015 | Krumm et al. 2015 |
128 | 4XES | Rhodopsin | NTS1 neurotensin receptor | Rat | 2.6 | activated (partially) | Neurotensin (8-13) | peptide | agonist | NA | NA | T4L-IL3 | X-RAY | 2015 | Krumm et al. 2015 |
129 | 4XNV | Rhodopsin | P2Y1 receptor | Human | 2.2 | inactive | BPTU | small molecule | antagonist | NA | NA | T4L-NT and Rubredoxin-IL3 | X-RAY | 2015 | Zhang et al. 2015 |
130 | 4XNW | Rhodopsin | P2Y1 receptor | Human | 2.7 | inactive | MRS2500 | small molecule | antagonist | NA | NA | T4L-NT and Rubredoxin-IL3 | X-RAY | 2015 | Zhang et al. 2015 |
131 | 4XT1 | Rhodopsin | Viral US28 receptor | Virus | 2.89 | activated | Human CX3CL1 | peptide | agonist | NA | Nanobody (intracellular) | NA | X-RAY | 2015 | Burg et al. 2015 |
132 | 4XT3 | Rhodopsin | Viral US28 receptor | Virus | 3.8 | activated | Human CX3CL1 | peptide | agonist | NA | NA | NA | X-RAY | 2015 | Burg et al. 2015 |
133 | 4YAY | Rhodopsin | AT1 angiotensin II type 1 receptor | Human | 2.9 | inactive | ZD7155 | small molecule | antagonist | NA | NA | BRIL-NT | X-RAY | 2015 | Zhang et al. 2015 |
134 | 4Z34 | Rhodopsin | LPA1 receptor | Human | 3.0 | inactive | ONO-9780307 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2015 | Chrencik et al. 2015 |
135 | 4Z35 | Rhodopsin | LPA1 receptor | Human | 2.9 | inactive | ONO-9780307 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2015 | Chrencik et al. 2015 |
136 | 4Z36 | Rhodopsin | LPA1 receptor | Human | 2.9 | inactive | ONO-3080573 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2015 | Chrencik et al. 2015 |
137 | 4ZJ8 | Rhodopsin | OX1 orexin receptor | Human | 2.75 | inactive | Suvorexant | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2016 | Yin et al. 2016 |
138 | 4ZJC | Rhodopsin | OX1 orexin receptor | Human | 2.83 | inactive | SB-674042 | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2016 | Yin et al. 2016 |
139 | 4ZUD | Rhodopsin | AT1 angiotensin II type 1 receptor | Human | 2.8 | inactive | Olmesartan | small molecule | antagonist | NA | NA | BRIL-NT | X-RAY | 2015 | Zhang et al. 2015 |
140 | 4ZWJ | Rhodopsin | Rhodopsin | Human | 3.3 | activated | All-trans-retinal | small molecule | agonist | Visual arrestin-1 (fused) | NA | T4L-NT | X-RAY | 2015 | Kang et al. 2015 |
141 | 5A8E | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.4 | inactive | 7-Methylcyanopindolol | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2015 | Sato et al. 2015 |
142 | 5C1M | Rhodopsin | Mu opioid receptor | Mouse | 2.1 | activated | BU72 | small molecule | agonist | NA | Nanobody (intracellular) | NA | X-RAY | 2015 | Huang et al. 2015 |
143 | 5CXV | Rhodopsin | M1 muscarinic receptor | Human | 2.7 | inactive | Tiotropium | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2016 | Thal et al. 2016 |
144 | 5D5A | Rhodopsin | Beta2 adrenergic receptor | Human | 2.48 | inactive | Carazolol | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2016 | Huang et al. 2016 |
145 | 5D5B | Rhodopsin | Beta2 adrenergic receptor | Human | 3.8 | inactive | Carazolol | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2016 | Huang et al. 2016 |
146 | 5D6L | Rhodopsin | Beta2 adrenergic receptor | Human | 3.2 | inactive | Carazolol | small molecule | inverse agonist | NA | NA | T4L | X-RAY | 2016 | Ma et al. 2016 |
147 | 5DGY | Rhodopsin | Rhodopsin | Human | 7.7 | activated | All-trans-retinal | small molecule | agonist | Visual arrestin-1 (fused) | NA | T4L-NT | X-RAY | 2016 | Zhou et al. 2016 |
148 | 5DHG | Rhodopsin | NOP nociceptin-orphanin FQ receptor | Human | 3.0 | inactive | C-35 | small molecule | antagonist | NA | NA | BRIL-NT | X-RAY | 2015 | Miller et al. 2015 |
149 | 5DHH | Rhodopsin | NOP nociceptin-orphanin FQ receptor | Human | 3.0 | inactive | SB-612111 | small molecule | antagonist | NA | NA | BRIL-NT | X-RAY | 2015 | Miller et al. 2015 |
150 | 5DSG | Rhodopsin | M4 muscarinic receptor | Human | 2.6 | inactive | Tiotropium | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2016 | Thal et al. 2016 |
151 | 5DYS | Rhodopsin | Rhodopsin | Bovine | 2.3 | activated | All-trans-retinal | small molecule | agonist | NA | NA | NA | X-RAY | 2016 | Singhal et al. 2016 |
152 | 5EN0 | Rhodopsin | Rhodopsin | Bovine | 2.81 | activated | All-trans-retinal | small molecule | agonist | NA | NA | NA | X-RAY | 2016 | Singhal et al. 2016 |
153 | 5F8U | Rhodopsin | Beta1 adrenergic receptor | Turkey | 3.35 | inactive | Cyanopindolol | small molecule | antagonist | NA | NA | NA | X-RAY | 2015 | Leslie et al. 2015 |
154 | 5G53 | Rhodopsin | A2A adenosine receptor | Human | 3.4 | activated | NECA | small molecule | agonist | Mini-Gs (alpha subunit) | NA | NA | X-RAY | 2016 | Carpenter et al. 2016 |
155 | 5IU4 | Rhodopsin | A2A adenosine receptor | Human | 1.72 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Segala et al. 2016 |
156 | 5IU7 | Rhodopsin | A2A adenosine receptor | Human | 1.9 | inactive | Comp. 12c | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Segala et al. 2016 |
157 | 5IU8 | Rhodopsin | A2A adenosine receptor | Human | 2.0 | inactive | Comp. 12f | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Segala et al. 2016 |
158 | 5IUA | Rhodopsin | A2A adenosine receptor | Human | 2.2 | inactive | Comp. 12b | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Segala et al. 2016 |
159 | 5IUB | Rhodopsin | A2A adenosine receptor | Human | 2.1 | inactive | Comp. 12x | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Segala et al. 2016 |
160 | 5JQH | Rhodopsin | Beta2 adrenergic receptor | Human | 3.2 | inactive | Carazolol | small molecule | inverse agonist | NA | Nanobody (intracellular) | T4L-NT | X-RAY | 2016 | Staus et al. 2016 |
161 | 3SN6 | Rhodopsin | Beta2 adrenergic receptor | Human | 3.2 | activated | BI-167107 | small molecule | agonist | Gs heterotrimer | Nanobody (bound to G protein) | T4L-NT | X-RAY | 2011 | Rasmussen et al. 2011b |
162 | 3UON | Rhodopsin | M2 muscarinic receptor | Human | 3.0 | inactive | 3-Quinuclidinyl benzilate (QNB, BZ) | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2012 | Haga et al. 2012 |
163 | 4OO9 | Glutamate | mGlu5 receptor | Human | 2.6 | inactive | Mavoglurant | small molecule | antagonist (negative allosteric modulator) | NA | NA | T4L-IL2 | X-RAY | 2014 | Dore et al. 2014 |
164 | 4OR2 | Glutamate | mGlu1 receptor | Human | 2.8 | inactive | FITM | small molecule | antagonist (negative allosteric modulator) | NA | NA | BRIL-NT | X-RAY | 2014 | Wu et al. 2014 |
165 | 5CGC | Glutamate | mGlu5 receptor | Human | 3.1 | inactive | Comp. 14 | small molecule | antagonist (negative allosteric modulator) | NA | NA | NA | X-RAY | 2015 | Christopher et al. 2015 |
166 | 5CGD | Glutamate | mGlu5 receptor | Human | 2.6 | inactive | Comp. 25 | small molecule | antagonist (negative allosteric modulator) | NA | NA | NA | X-RAY | 2015 | Christopher et al. 2015 |
167 | 5GLH | Rhodopsin | ETB endothelin receptor | Human | 2.8 | activated | Endothelin-1 | peptide | agonist | NA | NA | T4L-IL3 | X-RAY | 2016 | Shihoya et al. 2016 |
168 | 5GLI | Rhodopsin | ETB endothelin receptor | Human | 2.5 | inactive | Unliganded | NA | NA | NA | NA | T4L-IL3 | X-RAY | 2016 | Shihoya et al. 2016 |
169 | 5K2A | Rhodopsin | A2A adenosine receptor | Human | 2.5 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Batyuk et al. 2016 |
170 | 5K2B | Rhodopsin | A2A adenosine receptor | Human | 2.5 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Batyuk et al. 2016 |
171 | 5K2C | Rhodopsin | A2A adenosine receptor | Human | 1.9 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Batyuk et al. 2016 |
172 | 5K2D | Rhodopsin | A2A adenosine receptor | Human | 1.9 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2016 | Batyuk et al. 2016 |
173 | 5TGZ | Rhodopsin | CB1 cannabinoid receptor | Human | 2.8 | inactive | AM6538 | small molecule | antagonist | NA | NA | Flavodoxin-IL3 | X-RAY | 2016 | Hua et al. 2016 |
174 | 5V56 | Frizzled | Smoothened | Human | 2.9 | inactive | TC114 | small molecule | antagonist | NA | NA | Flavodoxin-IL3 | X-RAY | 2017 | Zhang et al. 2017 |
175 | 5V57 | Frizzled | Smoothened | Human | 3.0 | inactive | TC114 | small molecule | antagonist | NA | NA | Flavodoxin-IL3 | X-RAY | 2017 | Zhang et al. 2017 |
176 | 5VEW | Secretin | GLP1 glucagon-like peptide receptor | Human | 2.7 | inactive | PF-06372222 | small molecule | antagonist (negative allosteric modulator) | NA | NA | T4L-IL2 | X-RAY | 2017 | Song et al. 2017 |
177 | 5VEX | Secretin | GLP1 glucagon-like peptide receptor | Human | 3.0 | inactive | NNC0640 | small molecule | antagonist (negative allosteric modulator) | NA | NA | T4L-IL2 | X-RAY | 2017 | Song et al. 2017 |
178 | 5XEZ | Secretin | Glucagon receptor | Human | 3.0 | inactive | NNC0640 | small molecule | antagonist (negative allosteric modulator) | NA | Fab (bound to extracellular domain) | T4L-IL2 | X-RAY | 2017 | Zhang et al. 2017 |
179 | 5XF1 | Secretin | Glucagon receptor | Human | 3.19 | inactive | NNC0640 | small molecule | antagonist (negative allosteric modulator) | NA | Fab (bound to extracellular domain) | T4L-IL2 | X-RAY | 2017 | Zhang et al. 2017 |
180 | 5LWE | Rhodopsin | CCR9 chemokine receptor | Human | 2.8 | inactive | Vercirnon | small molecule | antagonist (allosteric) | NA | NA | NA | X-RAY | 2016 | Oswald et al. 2016 |
181 | 5NDD | Rhodopsin | PAR2 proteinase-activated receptor | Human | 2.8 | inactive | AZ8838 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Cheng et al. 2017 |
182 | 5NDZ | Rhodopsin | PAR2 proteinase-activated receptor | Human | 3.6 | inactive | AZ3451 | small molecule | antagonist (allosteric) | NA | NA | BRIL-IL3 | X-RAY | 2017 | Cheng et al. 2017 |
183 | 5NJ6 | Rhodopsin | PAR2 proteinase-activated receptor | Human | 4.0 | inactive | AZ7188 | small molecule | antagonist | NA | Fab (extracellular) | BRIL-IL3 | X-RAY | 2017 | Cheng et al. 2017 |
184 | 5T04 | Rhodopsin | NTS1 neurotensin receptor | Rat | 3.3 | activated | Neurotensin (8-13) | peptide | agonist | NA | NA | T4L-IL3 | X-RAY | 2016 | Krumm et al. 2016 |
185 | 5T1A | Rhodopsin | CCR2 chemokine receptor | Human | 2.81 | inactive | BMS-681 + CCR2-RA-[R] | small molecule | antagonist + allosteric antagonist | NA | NA | T4L-IL3 | X-RAY | 2016 | Zheng et al. 2016 |
186 | 5TE3 | Rhodopsin | Rhodopsin | Bovine | 2.7 | activated | Unliganded | NA | NA | NA | NA | NA | X-RAY | 2017 | Gulati et al. 2017 |
187 | 5TE5 | Rhodopsin | Rhodopsin | Bovine | 4.01 | inactive | Six-carbon ring retinal chromophore (Rh6mr) | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2017 | Gulati et al. 2017 |
188 | 5TVN | Rhodopsin | 5-HT2B serotonin receptor | Human | 2.9 | inactive or minimally activated | LSD | small molecule | agonist (biased, beta-arrestin) | NA | NA | BRIL-IL3 | X-RAY | 2017 | Wacker et al. 2017 |
189 | 5U09 | Rhodopsin | CB1 cannabinoid receptor | Human | 2.6 | inactive | Taranabant | small molecule | inverse agonist | NA | NA | PGS-IL3 | X-RAY | 2016 | Shao et al. 2016 |
190 | 5UEN | Rhodopsin | A1 adenosine receptor | Human | 3.2 | inactive | DU172 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Glukhova et al. 2017 |
191 | 5UIG | Rhodopsin | A2A adenosine receptor | Human | 3.5 | inactive | Comp. 1 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Sun et al. 2017 |
192 | 5UNF | Rhodopsin | AT2 angiotensin II type 2 receptor | Human | 2.8 | activated (active-like) | Comp. 1 | small molecule | ligand | NA | NA | BRIL-NT | X-RAY | 2017 | Zhang et al. 2017 |
193 | 5UNG | Rhodopsin | AT2 angiotensin II type 2 receptor | Human | 2.8 | activated (active-like) | Comp. 1 | small molecule | ligand | NA | NA | BRIL-NT | X-RAY | 2017 | Zhang et al. 2017 |
194 | 5UNH | Rhodopsin | AT2 angiotensin II type 2 receptor | Human | 2.9 | activated (active-like) | Comp. 2 | small molecule | ligand | NA | NA | BRIL-NT | X-RAY | 2017 | Zhang et al. 2017 |
195 | 5UVI | Rhodopsin | A2A adenosine receptor | Human | 3.2 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Martin-Garcia et al. 2017 |
196 | 5JTB | Rhodopsin | A2A adenosine receptor | Human | 2.8 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Melnikov et al. 2017 |
197 | 5TZR | Rhodopsin | FFA1 receptor (GPR40) | Human | 2.2 | inactive or minimally activated | MK-8666 | small molecule | partial agonist | NA | NA | T4L-IL3 | X-RAY | 2017 | Lu et al. 2017 |
198 | 5TZY | Rhodopsin | FFA1 receptor (GPR40) | Human | 3.22 | inactive or minimally activated | MK-8666 + AP8 | small molecule | partial agonist + full allosteric agonist | NA | NA | T4L-IL3 | X-RAY | 2017 | Lu et al. 2017 |
199 | 5NX2 | Secretin | GLP1 glucagon-like peptide receptor | Human | 3.7 | activated | Peptide 5 | peptide | agonist | NA | NA | BRIL-NT | X-RAY | 2017 | Jazayeri et al. 2017 |
200 | 5KW2 | Rhodopsin | FFA1 receptor (GPR40) | Human | 2.76 | inactive or minimally activated | TAK-875 | small molecule | partial agonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Ho et al. 2018 |
201 | 5MZJ | Rhodopsin | A2A adenosine receptor | Human | 2.0 | inactive | Theophylline | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Cheng et al. 2017 |
202 | 5MZP | Rhodopsin | A2A adenosine receptor | Human | 2.1 | inactive | Caffeine | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Cheng et al. 2017 |
203 | 5N2R | Rhodopsin | A2A adenosine receptor | Human | 2.8 | inactive | PSB36 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Cheng et al. 2017 |
204 | 5N2S | Rhodopsin | A1 adenosine receptor | Human | 3.3 | inactive | PSB36 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Cheng et al. 2017 |
205 | 5NLX | Rhodopsin | A2A adenosine receptor | Human | 2.14 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Weinert et al. 2017 |
206 | 5NM2 | Rhodopsin | A2A adenosine receptor | Human | 1.95 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Weinert et al. 2017 |
207 | 5NM4 | Rhodopsin | A2A adenosine receptor | Human | 1.7 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Weinert et al. 2017 |
208 | 5O9H | Rhodopsin | C5a1 complement peptide receptor | Human | 2.7 | inactive | NDT9513727 | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2018 | Robertson et al. 2018 |
209 | 5OLG | Rhodopsin | A2A adenosine receptor | Human | 1.87 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Rucktooa et al. 2018 |
210 | 5OLH | Rhodopsin | A2A adenosine receptor | Human | 2.6 | inactive | Vipadenant | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Rucktooa et al. 2018 |
211 | 5OLO | Rhodopsin | A2A adenosine receptor | Human | 3.1 | inactive | Tozadenant | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Rucktooa et al. 2018 |
212 | 5OLV | Rhodopsin | A2A adenosine receptor | Human | 2.0 | inactive | LUAA47070 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Rucktooa et al. 2018 |
213 | 5OLZ | Rhodopsin | A2A adenosine receptor | Human | 1.9 | inactive | Comp. 4e | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Rucktooa et al. 2018 |
214 | 5OM1 | Rhodopsin | A2A adenosine receptor | Human | 2.1 | inactive | Comp. 4e | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Rucktooa et al. 2018 |
215 | 5OM4 | Rhodopsin | A2A adenosine receptor | Human | 2.0 | inactive | Comp. 4e | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Rucktooa et al. 2018 |
216 | 5TUD | Rhodopsin | 5-HT2B serotonin receptor | Human | 3.0 | activated | Ergotamine | small molecule | agonist | NA | Fab (extracellular) | BRIL-IL3 | X-RAY | 2017 | Ishchenko et al. 2017 |
217 | 5UIW | Rhodopsin | CCR5 chemokine receptor | Human | 2.2 | inactive | 5P7-CCL5 | peptide | antagonist | NA | NA | Rubredoxin-IL3 | X-RAY | 2017 | Zheng et al. 2017 |
218 | 5V54 | Rhodopsin | 5-HT1B serotonin receptor | Human | 3.9 | inactive | Methiothepin | small molecule | antagonist | NA | NA | OB1 BRIL-IL3 | X-RAY | 2018 | Yin et al. 2018 |
219 | 5W0P | Rhodopsin | Rhodopsin | Human | 3.01 | activated | Unliganded | NA | NA | Visual arrestin | NA | T4L-NT | X-RAY | 2017 | Zhou et al. 2017 |
220 | 5WF6 | Rhodopsin | A2A adenosine receptor | Human | 2.9 | activated (partially) | UK432097 | small molecule | agonist | NA | NA | T4L-IL3 | X-RAY | 2018 | White et al. 2018 |
221 | 5WIU | Rhodopsin | D4 dopamine receptor | Human | 1.96 | inactive | Nemonapride | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Wang et al. 2017 |
222 | 5WIV | Rhodopsin | D4 dopamine receptor | Human | 2.14 | inactive | Nemonapride | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Wang et al. 2017 |
223 | 5WKT | Rhodopsin | Rhodopsin | Bovine | 3.2 | activated | Beta-octylglucoside | small molecule | NA | Gt peptide | NA | NA | X-RAY | 2017 | Broecker et al. 2017 |
224 | 5WQC | Rhodopsin | OX2 orexin receptor | Human | 1.96 | inactive | EMPA | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2017 | Suno et al. 2017 |
225 | 5WS3 | Rhodopsin | OX2 orexin receptor | Human | 2.3 | inactive | EMPA | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2017 | Suno et al. 2017 |
226 | 5X7D | Rhodopsin | Beta2 adrenergic receptor | Human | 2.7 | inactive | Carazolol + Comp. 15 | small molecule | antagonist + allosteric antagonist (intracellular) | NA | NA | T4L-IL3 | X-RAY | 2017 | Liu et al. 2017 |
227 | 5X93 | Rhodopsin | ETB endothelin receptor | Human | 2.2 | inactive | K-8794 | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2017 | Shihoya et al. 2017 |
228 | 5XPR | Rhodopsin | ETB endothelin receptor | Human | 3.6 | inactive | Bosentan | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2017 | Shihoya et al. 2017 |
229 | 5XR8 | Rhodopsin | CB1 cannabinoid receptor | Human | 2.95 | activated | Hexahydrocannabinol (AM841) | small molecule | agonist | NA | NA | Flavodoxin-IL3 | X-RAY | 2017 | Hua et al. 2017 |
230 | 5XRA | Rhodopsin | CB1 cannabinoid receptor | Human | 2.8 | activated | Tetrahydrocannabinol (AM11542) | small molecule | agonist | NA | NA | Flavodoxin-IL3 | X-RAY | 2017 | Hua et al. 2017 |
231 | 5XSZ | Rhodopsin | LPA6 receptor | Zebrafish | 3.2 | inactive | Unliganded (acyl chain of crystallization lipid in binding pocket) | NA | NA | NA | NA | T4L-IL3 | X-RAY | 2017 | Taniguchi et al. 2017 |
232 | 5ZBH | Rhodopsin | Y1 neuropeptide receptor | Human | 3.0 | inactive | BMS-193885 | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Yang et al. 2018 |
233 | 5ZBQ | Rhodopsin | Y1 neuropeptide receptor | Human | 2.7 | inactive | UR-MK299 | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Yang et al. 2018 |
234 | 6AQF | Rhodopsin | A2A adenosine receptor | Human | 2.51 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Eddy et al. 2018 |
235 | 6B73 | Rhodopsin | Kappa opioid receptor | Human | 3.1 | activated | MP1104 | small molecule | agonist | NA | Nanobody (intracellular) | NA | X-RAY | 2018 | Che et al. 2018 |
236 | 6BQG | Rhodopsin | 5-HT2C serotonin receptor | Human | 3.0 | activated | Ergotamine | small molecule | agonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Peng et al. 2018 |
237 | 6BQH | Rhodopsin | 5-HT2C serotonin receptor | Human | 2.7 | inactive | Ritanserin | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Peng et al. 2018 |
238 | 6CM4 | Rhodopsin | D2 dopamine receptor | Human | 2.87 | inactive | Risperidone | small molecule | inverse agonist | NA | NA | T4-IL3 | X-RAY | 2018 | Wang et al. 2018 |
239 | 6FK6 | Rhodopsin | Rhodopsin | Bovine | 2.36 | activated | RS01 | small molecule | agonist | NA | NA | NA | X-RAY | 2018 | Mattle et al. 2018 |
240 | 6FK7 | Rhodopsin | Rhodopsin | Bovine | 2.62 | activated | RS06 | small molecule | agonist | NA | NA | NA | X-RAY | 2018 | Mattle et al. 2018 |
241 | 6FK8 | Rhodopsin | Rhodopsin | Bovine | 2.87 | activated | RS08 | small molecule | agonist | NA | NA | NA | X-RAY | 2018 | Mattle et al. 2018 |
242 | 6FK9 | Rhodopsin | Rhodopsin | Bovine | 2.63 | activated | RS09 | small molecule | agonist | NA | NA | NA | X-RAY | 2018 | Mattle et al. 2018 |
243 | 6FKA | Rhodopsin | Rhodopsin | Bovine | 2.7 | activated | RS11 | small molecule | agonist | NA | NA | NA | X-RAY | 2018 | Mattle et al. 2018 |
244 | 6FKB | Rhodopsin | Rhodopsin | Bovine | 3.03 | activated | RS13 | small molecule | agonist | NA | NA | NA | X-RAY | 2018 | Mattle et al. 2018 |
245 | 6FKC | Rhodopsin | Rhodopsin | Bovine | 2.46 | activated | RS15 | small molecule | agonist | NA | NA | NA | X-RAY | 2018 | Mattle et al. 2018 |
246 | 6FKD | Rhodopsin | Rhodopsin | Bovine | 2.49 | activated | RS16 | small molecule | agonist | NA | NA | NA | X-RAY | 2018 | Mattle et al. 2018 |
247 | 6FFH | Glutamate | mGlu5 receptor | Human | 2.65 | inactive | Fenobam | small molecule | antagonist + allosteric antagonist (negative allosteric modulator) | NA | NA | T4L-IL2 | X-RAY | 2018 | Christopher et al. 2018 |
248 | 6FFI | Glutamate | mGlu5 receptor | Human | 2.2 | inactive | M-MPEP | small molecule | antagonist + allosteric antagonist (negative allosteric modulator) | NA | NA | T4L-IL2 | X-RAY | 2018 | Christopher et al. 2018 |
249 | 6D32 | Frizzled | Smoothened | Xenopus | 3.75 | inactive | Cyclopamine | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Huang et al. 2018 |
250 | 6D35 | Frizzled | Smoothened | Xenopus | 3.9 | inactive or minimally activated | Cholesterol | small molecule | agonist (allosteric, bound to extracellular CRD) | NA | NA | BRIL-IL3 | X-RAY | 2018 | Huang et al. 2018 |
251 | 5WB2 | Rhodopsin | Viral US28 receptor | Virus | 3.5 | activated | CX3CL1.35 | peptide | agonist | NA | Nanobody (intracellular) | NA | X-RAY | 2018 | Miles et al. 2018 |
252 | 5WF5 | Rhodopsin | A2A adenosine receptor | Human | 2.6 | activated (partially) | UK432097 | small molecule | agonist | NA | NA | T4L-IL3 | X-RAY | 2018 | White et al. 2018 |
253 | 5XJM | Rhodopsin | AT2 angiotensin II type 2 receptor | Human | 3.2 | activated | [Sar1, Ile8]Angiotensin II | peptide | agonist | NA | Fab (extracellular) | BRIL-IL3 | X-RAY | 2018 | Asada et al. 2018 |
254 | 6BD4 | Frizzled | FZD4 frizzled receptor | Human | 2.4 | inactive | Unliganded | NA | NA | NA | NA | Rubredoxin-IL3 | X-RAY | 2018 | Yang et al. 2018 |
255 | 6DRX | Rhodopsin | 5-HT2B serotonin receptor | Human | 3.1 | inactive | Lisuride | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | McCorvy et al. 2018 |
256 | 6DRY | Rhodopsin | 5-HT2B serotonin receptor | Human | 2.92 | inactive or minimally activated | Methylergonovine | small molecule | agonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | McCorvy et al. 2018 |
257 | 6DRZ | Rhodopsin | 5-HT2B serotonin receptor | Human | 3.1 | inactive or minimally activated | Methysergide | small molecule | partial agonist (antagonist for wild type receptor) | NA | NA | BRIL-IL3 | X-RAY | 2018 | McCorvy et al. 2018 |
258 | 6DS0 | Rhodopsin | 5-HT2B serotonin receptor | Human | 3.19 | inactive or minimally activated | LY266097 | small molecule | partial agonist (biased, Gq) | NA | NA | BRIL-IL3 | X-RAY | 2018 | McCorvy et al. 2018 |
259 | 6FUF | Rhodopsin | Rhodopsin | Bovine | 3.12 | activated | All-trans-retinal | small molecule | agonist | Mini-Go (alpha subunit) | NA | NA | X-RAY | 2018 | Tsai et al. 2018 |
260 | 6FJ3 | Secretin | PTH1 parathyroid hormone receptor | Human | 2.5 | inactive | Parathyroid hormone | peptide | agonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2018 | Ehrenmann et al. 2018 |
261 | 5YC8 | Rhodopsin | M2 muscarinic receptor | Human | 2.5 | inactive | NMS | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Suno et al. 2018 |
262 | 5ZHP | Rhodopsin | M3 muscarinic receptor | Rat | 3.1 | inactive | Comp. 6o (BS46) | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Liu et al. 2018 |
263 | 5ZK3 | Rhodopsin | M2 muscarinic receptor | Human | 2.6 | inactive | QNB (3-Quinuclidinyl benzilate, BZ) | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Suno et al. 2018 |
264 | 5ZK8 | Rhodopsin | M2 muscarinic receptor | Human | 3.0 | inactive | NMS | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Suno et al. 2018 |
265 | 5ZKB | Rhodopsin | M2 muscarinic receptor | Human | 2.95 | inactive | AF-DX 384 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Suno et al. 2018 |
266 | 5ZKC | Rhodopsin | M2 muscarinic receptor | Human | 2.3 | inactive | NMS | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2018 | Suno et al. 2018 |
267 | 5ZTY | Rhodopsin | CB2 cannabinoid receptor | Human | 2.8 | inactive | AM10257 | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Li et al. 2019 |
268 | 6A93 | Rhodopsin | 5-HT2A serotonin receptor | Human | 3.0 | inactive | Risperidone | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Kimura et al. 2019 |
269 | 6A94 | Rhodopsin | 5-HT2A serotonin receptor | Human | 2.9 | inactive | Zotepine | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Kimura et al. 2019 |
270 | 6AKX | Rhodopsin | CCR5 chemokine receptor | Human | 2.8 | inactive | Comp. 21 | small molecule | antagonist | NA | NA | Rubredoxin-IL3 | X-RAY | 2018 | Peng et al. 2018 |
271 | 6AKY | Rhodopsin | CCR5 chemokine receptor | Human | 2.8 | inactive | Comp. 34 | small molecule | antagonist | NA | NA | Rubredoxin-IL3 | X-RAY | 2018 | Peng et al. 2018 |
272 | 6DO1 | Rhodopsin | AT1 angiotensin II type 1 receptor | Human | 2.9 | activated | S1I8 | peptide | partial agonist | NA | Nanobody (intracellular) | BRIL-IL3 (not visible) | X-RAY | 2019 | Wingler et al. 2019 |
273 | 6E59 | Rhodopsin | NK1 tachykinin receptor (substance-P receptor) | Human | 3.4 | inactive | L760735 | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2018 | Yin et al. 2018 |
274 | 6GPS | Rhodopsin | CCR2 chemokine receptor | Human | 3.3 | inactive | MK-0812 | small molecule | antagonist | NA | NA | Rubredoxin-IL3 | X-RAY | 2019 | Apel et al. 2019 |
275 | 6GPX | Rhodopsin | CCR2 chemokine receptor | Human | 2.7 | inactive | MK-0812 | small molecule | antagonist | NA | NA | Rubredoxin-IL3 | X-RAY | 2019 | Apel et al. 2019 |
276 | 6HLO | Rhodopsin | NK1 tachykinin receptor (substance-P receptor) | Human | 2.4 | inactive | Aprepitant | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2019 | Schoppe et al. 2019 |
277 | 6HLP | Rhodopsin | NK1 tachykinin receptor (substance-P receptor) | Human | 2.2 | inactive | Netupitant | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2019 | Schoppe et al. 2019 |
278 | 6IBL | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.7 | activated | Formoterol | small molecule | agonist | NA | Nanobody (intracellular) | Thioredoxin-NT | X-RAY | 2019 | Warne et al. 2019 |
279 | 6IGK | Rhodopsin | ETB endothelin receptor | Human | 2.0 | Activated (partially) | Endothelin-3 | peptide | agonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Shihoya et al. 2018 |
280 | 6IGL | Rhodopsin | ETB endothelin receptor | Human | 2.7 | inactive or minimally activated | IRL1620 | peptide | partial agonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Shihoya et al. 2018 |
281 | 6J20 | Rhodopsin | NK1 tachykinin receptor (substance-P receptor) | Human | 2.7 | inactive | Aprepitant | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Chen et al. 2019 |
282 | 6J21 | Rhodopsin | NK1 tachykinin receptor (substance-P receptor) | Human | 3.2 | inactive | Aprepitant | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Chen et al. 2019 |
283 | 6ME2 | Rhodopsin | MT1 melatonin receptor | Human | 2.8 | inactive or minimally activated | Ramelteon | small molecule | agonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2019 | Stauch et al. 2019 |
284 | 6ME3 | Rhodopsin | MT1 melatonin receptor | Human | 2.9 | inactive or minimally activated | 2-Phenylmelatonin | small molecule | agonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2019 | Stauch et al. 2019 |
285 | 6ME4 | Rhodopsin | MT1 melatonin receptor | Human | 3.2 | inactive or minimally activated | 2-Iodomelatonin | small molecule | agonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2019 | Stauch et al. 2019 |
286 | 6ME5 | Rhodopsin | MT1 melatonin receptor | Human | 3.2 | inactive or minimally activated | Agomelatine | small molecule | agonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2019 | Stauch et al. 2019 |
287 | 6ME6 | Rhodopsin | MT2 melatonin receptor | Human | 2.8 | inactive or minimally activated | 2-Phenylmelatonin | small molecule | agonist | NA | NA | BRIL-NT and Rubredoxin-IL3 | X-RAY | 2019 | Johansson et al. 2019 |
288 | 6ME7 | Rhodopsin | MT2 melatonin receptor | Human | 3.2 | inactive or minimally activated | 2-Phenylmelatonin | small molecule | agonist | NA | NA | BRIL-NT and Rubredoxin-IL3 | X-RAY | 2019 | Johansson et al. 2019 |
289 | 6ME8 | Rhodopsin | MT2 melatonin receptor | Human | 3.1 | inactive or minimally activated | 2-Phenylmelatonin | small molecule | agonist | NA | NA | BRIL-NT and Rubredoxin-IL3 | X-RAY | 2019 | Johansson et al. 2019 |
290 | 6ME9 | Rhodopsin | MT2 melatonin receptor | Human | 3.3 | inactive or minimally activated | Ramelteon | small molecule | agonist | NA | NA | BRIL-NT and Rubredoxin-IL3 | X-RAY | 2019 | Johansson et al. 2019 |
291 | 6MH8 | Rhodopsin | A2A adenosine receptor | Human | 4.2 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Martin-Garcia et al. 2019 |
292 | 6MXT | Rhodopsin | Beta2 adrenergic receptor | Human | 2.96 | activated | Salmeterol | small molecule | agonist | NA | Nanobody (intracellular) | T4L-NT | X-RAY | 2018 | Masureel et al. 2018 |
294 | 5WB1 | Rhodopsin | Viral US28 receptor | Virus | 3.51 | activated | Unliganded | NA | NA | NA | Nanobody (intracellular) | NA | X-RAY | 2018 | Miles et al. 2018 |
295 | 5X33 | Rhodopsin | BLT1 leukotriene B4 receptor | Guinea Pig | 3.7 | inactive | BIIL260 | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Hori et al. 2018 |
296 | 6AK3 | Rhodopsin | EP3 prostanoid receptor (prostaglandin E receptor 3) | Human | 2.9 | activated (active-like) | Prostaglandin E2 | small molecule | agonist | NA | NA | BRIL-IL3 (not visible) | X-RAY | 2018 | Morimoto et al. 2018 |
297 | 6D26 | Rhodopsin | DP2 prostanoid receptor (prostaglandin D2 receptor 2, CRTH2) | Human | 2.8 | inactive | Fevipiprant | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Wang et al. 2018 |
298 | 6D27 | Rhodopsin | DP2 prostanoid receptor (prostaglandin D2 receptor 2, CRTH2) | Human | 2.74 | inactive | CAY10471 | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Wang et al. 2018 |
299 | 6IIU | Rhodopsin | TP prostanoid receptor (thromboxane A2 receptor) | Human | 2.5 | inactive | Ramatroban | small molecule | antagonist | NA | NA | BRIL-NT and Rubredoxin-IL3 | X-RAY | 2018 | Fan et al. 2018 |
300 | 6IIV | Rhodopsin | TP prostanoid receptor (thromboxane A2 receptor) | Human | 3.0 | inactive | Daltroban | small molecule | antagonist | NA | NA | BRIL-NT and Rubredoxin-IL3 | X-RAY | 2018 | Fan et al. 2018 |
301 | 5ZKQ | Rhodopsin | PAF receptor | Human | 2.9 | inactive | ABT-491 | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Cao et al. 2018 |
302 | 5ZKP | Rhodopsin | PAF receptor | Human | 2.81 | inactive | SR 27417 | small molecule | antagonist | NA | NA | Flavodoxin-IL3 | X-RAY | 2018 | Cao et al. 2018 |
303 | 5YHL | Rhodopsin | EP4 prostanoid receptor (prostaglandin E receptor 4) | Human | 4.2 | inactive | ONO-9990614 | small molecule | antagonist | NA | Fab (extracellular) | NA | X-RAY | 2018 | Toyoda et al. 2018 |
304 | 5YWY | Rhodopsin | EP4 prostanoid receptor (prostaglandin E receptor 4) | Human | 3.2 | inactive | ONO-AE3-208 | small molecule | antagonist | NA | Fab (extracellular) | NA | X-RAY | 2018 | Toyoda et al. 2018 |
305 | 6M9T | Rhodopsin | EP3 prostanoid receptor (prostaglandin E receptor 3) | Human | 2.5 | Activated (partially) | Misoprostol-FA | small molecule | agonist | NA | NA | T4L-IL3 | X-RAY | 2018 | Audet et al. 2018 |
311 | 2LNL | Rhodopsin | CXCR1 chemokine receptor | Human | 0.0 | NA | Unliganded | NA | NA | NA | NA | NA | NMR | 2012 | Park et al. 2012 |
312 | 6CMO | Rhodopsin | Rhodopsin | Human | 4.5 | activated | NA | NA | NA | Gi heterotrimer | Fab (bound to G protein) | NA | Electron Microscopy | 2018 | Kang et al. 2018 |
313 | 5VBL | Rhodopsin | Apelin receptor | Human | 2.6 | inactive | AMG3054 | peptide | agonist | NA | NA | Rubredoxin-IL3 | X-RAY | 2017 | Ma et al. 2017 |
314 | 5VRA | Rhodopsin | A2A adenosine receptor | Human | 2.35 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2017 | Broecker et al. 2017 |
315 | 6D9H | Rhodopsin | A1 adenosine receptor | Human | 3.6 | activated | Adenosine | small molecule | agonist | Gi heterotrimer | NA | NA | Electron Microscopy | 2018 | Draper-Joyce et al. 2018 |
316 | 6DDE | Rhodopsin | Mu opioid receptor | Human | 3.5 | activated | DAMGO | peptide | agonist | Gi heterotrimer | ScFv (bound to G protein) | NA | Electron Microscopy | 2018 | Koehl et al. 2018 |
317 | 6DDF | Rhodopsin | Mu opioid receptor | Human | 3.5 | activated | DAMGO | peptide | agonist | Gi heterotrimer | NA | NA | Electron Microscopy | 2018 | Koehl et al. 2018 |
318 | 6G79 | Rhodopsin | 5-HT1B serotonin receptor | Human | 3.78 | activated | Donitriptan | small molecule | agonist | Go heterotrimer | NA | NA | Electron Microscopy | 2018 | Garcia-Nafria et al. 2018 |
319 | 6GDG | Rhodopsin | A2A adenosine receptor | Human | 4.11 | activated | NECA | small molecule | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2018 | Garcia-Nafria et al. 2018 |
320 | 6H7J | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.8 | activated | Isoprenaline | small molecule | agonist | NA | Nanobody (intracellular) | Thioredoxin-NT | X-RAY | 2018 | Warne et al. 2018 |
321 | 6H7L | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.7 | activated | Dobutamine | small molecule | agonist | NA | Nanobody (intracellular) | Thioredoxin-NT | X-RAY | 2018 | Warne et al. 2018 |
322 | 6H7M | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.76 | activated | Salbutamol | small molecule | agonist | NA | Nanobody (intracellular) | Thioredoxin-NT | X-RAY | 2018 | Warne et al. 2018 |
323 | 6H7N | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.5 | activated | Xamoterol | small molecule | agonist | NA | Nanobody (intracellular) | Thioredoxin-NT | X-RAY | 2018 | Warne et al. 2018 |
324 | 6H7O | Rhodopsin | Beta1 adrenergic receptor | Turkey | 2.8 | activated | Cyanopindolol | small molecule | agonist | NA | Nanobody (intracellular) | Thioredoxin-NT | X-RAY | 2018 | Warne et al. 2018 |
325 | 6HLL | Rhodopsin | NK1 tachykinin receptor (substance-P receptor) | Human | 3.27 | inactive | CP-99,994 | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2019 | Schoppe et al. 2019 |
326 | 6MEO | Rhodopsin | CCR5 chemokine receptor | Human | 3.9 | inactive | T-cell surface glycoprotein CD4 + HIV envelope glycoprotein gp160 | protein | NA | NA | NA | NA | Electron Microscopy | 2018 | Shaik et al. 2018 |
327 | 6MET | Rhodopsin | CCR5 chemokine receptor | Human | 4.5 | inactive | T-cell surface glycoprotein CD4 + HIV envelope glycoprotein gp160 | protein | NA | NA | NA | NA | Electron Microscopy | 2018 | Shaik et al. 2018 |
328 | 6N4B | Rhodopsin | CB1 cannabinoid receptor | Human | 3.0 | activated | FUB | small molecule | agonist | Gi heterotrimer | ScFv (bound to G protein) | NA | Electron Microscopy | 2019 | Krishna Kumar et al. 2019 |
329 | 6OIJ | Rhodopsin | M1 muscarinic receptor | Human | 3.3 | activated | Iperoxo | small molecule | agonist | G11 heterotrimer | ScFv (bound to G protein) | NA | Electron Microscopy | 2019 | Maeda et al. 2019 |
330 | 6OIK | Rhodopsin | M2 muscarinic receptor | Human | 3.6 | activated | Iperoxo | small molecule | agonist | Go heterotrimer | ScFv (bound to G protein) | NA | Electron Microscopy | 2019 | Maeda et al. 2019 |
331 | 6N51 | Glutamate | mGlu5 receptor | Human | 4.0 | activated dimer | Quisqualate | small molecule | agonist | NA | Nanobody (bound to extracellular domain) | NA | Electron Microscopy | 2019 | Koehl et al. 2019 |
332 | 6N52 | Glutamate | mGlu5 receptor | Human | 4.0 | inactive | Unliganded | NA | NA | NA | Nanobody (bound to extracellular domain, not visible) | NA | Electron Microscopy | 2019 | Koehl et al. 2019 |
333 | 6NIY | Secretin | CT calcitonin receptor | Human | 3.34 | activated | Salmon calcitonin (sCT) | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2019 | Dal Maso et al. 2019 |
334 | 5UZ7 | Secretin | CT calcitonin receptor | Human | 4.1 | activated | Salmon calcitonin (sCT) | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2017 | Liang et al. 2017 |
335 | 6E3Y | Secretin | CT calcitonin receptor | Human | 3.34 | activated | Salmon calcitonin (sCT) | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2018 | Liang et al. 2018 |
336 | 5VAI | Secretin | GLP1 glucagon-like peptide receptor | Rabbit | 4.1 | activated | GLP-1 | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2017 | Zhang et al. 2017 |
337 | 6B3J | Secretin | GLP1 glucagon-like peptide receptor | Human | 3.3 | activated | Exendin-P5 | peptide | agonist (biased, G protein) | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2018 | Liang et al. 2018 |
338 | 6NBF | Secretin | PTH1 parathyroid hormone receptor | Rat | 3.0 | activated | LA-PTH | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2019 | Zhao et al. 2019 |
339 | 6NBH | Secretin | PTH1 parathyroid hormone receptor | Rat | 3.5 | activated | LA-PTH | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2019 | Zhao et al. 2019 |
340 | 6NBI | Secretin | PTH1 parathyroid hormone receptor | Rat | 4.0 | activated | LA-PTH | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2019 | Zhao et al. 2019 |
341 | 6O3C | Frizzled | Smoothened | Mouse | 2.8 | activated | SAG21k | small molecule | agonist | NA | Nanobody (intracellular) | NA | X-RAY | 2019 | Deshpande et al. 2019 |
342 | 6OT0 | Frizzled | Smoothened | Human | 3.84 | activated | 24,25-epoxycholesterol | small molecule | agonist | Gi1 heterotrimer | Fab (bound to G protein) | NA | Electron Microscopy | 2019 | Qi et al. 2019 |
343 | 6E67 | Rhodopsin | Beta2 adrenergic receptor | Human | 3.7 | activated | BI-167107 | small molecule | agonist | Gs peptide (fused) | NA | NA | X-RAY | 2019 | Liu et al. 2019 |
344 | 6GT3 | Rhodopsin | A2A adenosine receptor | Human | 2.0 | inactive | AZD4635 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Borodovsky et al. 2019 |
345 | 6I9K | Rhodopsin | Rhodopsin-1 | Jumping Spider | 2.14 | inactive | 9-Cis-retinal | small molecule | inverse agonist | NA | NA | NA | X-RAY | 2019 | Varma et al. 2019 |
346 | 6IBB | Rhodopsin | Succinate receptor 1 | Rat | 2.12 | inactive | Unliganded | NA | NA | NA | Nanobody (intracellular) | NA | X-RAY | 2019 | Haffke et al. 2019 |
347 | 6K1Q | Rhodopsin | ETB endothelin receptor | Human | 2.7 | inactive | IRL2500 | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Nagiri et al. 2019 |
348 | 6KQI | Rhodopsin | CB1 cannabinoid receptor | Human | 3.24 | inactive or minimally activated (intermediate) | CP55940 + ORG27569 | small molecule | agonist + negative allosteric modulator | NA | NA | Glycogen synthase-IL3 | X-RAY | 2019 | Shao et al. 2019 |
349 | 6N48 | Rhodopsin | Beta2 adrenergic receptor | Human | 3.2 | activated | BI-167107 + positive allosteric modulator | small molecule | agonist + positive allosteric modulator | NA | Nanobody (intracellular) | T4L-NT | X-RAY | 2019 | Liu et al. 2019 |
350 | 6OFJ | Rhodopsin | Rhodopsin | Bovine | 4.5 | inactive | NA | NA | NA | NA | NA | NA | Electron Microscopy | 2019 | Zhao et al. 2019 |
351 | 6OS9 | Rhodopsin | NTS1 neurotensin receptor | Human | 3.0 | activated (partially) | JMV449 | small molecule | agonist | Gi1 heterotrimer | ScFv (bound to G protein) | NA | Electron Microscopy | 2019 | Kato et al. 2019 |
352 | 6OSA | Rhodopsin | NTS1 neurotensin receptor | Human | 3.0 | activated (partially) | JMV449 | small molecule | agonist | Gi1 heterotrimer | NA | NA | Electron Microscopy | 2019 | Kato et al. 2019 |
353 | 6OY9 | Rhodopsin | Rhodopsin | Bovine | 3.9 | activated | All-trans-retinal | small molecule | agonist | Gt heterotrimer | NA | NA | Electron Microscopy | 2019 | Gao et al. 2019 |
354 | 6OYA | Rhodopsin | Rhodopsin | Bovine | 3.3 | activated | All-trans-retinal | small molecule | agonist | Gt heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2019 | Gao et al. 2019 |
355 | 6QNO | Rhodopsin | Rhodopsin | Human | 4.38 | activated | All-trans-retinal | small molecule | agonist | Gi1 heterotrimer | Fab (bound to G protein) | NA | Electron Microscopy | 2019 | Tsai et al. 2019 |
356 | 6QZH | Rhodopsin | CCR7 chemokine receptor | Human | 2.1 | inactive | Cmp2105 | small molecule | allosteric antagonist (intracellular) | NA | NA | Sialidase A-IL3 | X-RAY | 2019 | Jaeger et al. 2019 |
357 | 6RNK | Rhodopsin | Succinate receptor 1 | Rat | 1.94 | inactive | NF-56-EJ40 | small molecule | antagonist | NA | Nanobody (intracellular) | NA | X-RAY | 2019 | Haffke et al. 2019 |
358 | 6JZH | Rhodopsin | A2A adenosine receptor | Human | 2.25 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Shimazu et al. 2019 |
359 | 6RZ4 | Rhodopsin | CysLT1 cysteinyl leukotriene receptor | Human | 2.7 | inactive | Pranlukast | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Luginina et al. 2019 |
360 | 6RZ5 | Rhodopsin | CysLT1 cysteinyl leukotriene receptor | Human | 2.53 | inactive | Zafirlukast | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Luginina et al. 2019 |
361 | 6KJV | Secretin | GLP1 glucagon-like peptide receptor | Human | 2.8 | inactive | PF-06372222 | small molecule | antagonist (negative allosteric modulator) | NA | NA | T4L-IL2 | X-RAY | 2019 | Xu et al. 2019 |
362 | 6KK1 | Secretin | GLP1 glucagon-like peptide receptor | Human | 2.8 | inactive | PF-06372222 | small molecule | antagonist (negative allosteric modulator) | NA | NA | T4L-IL2 | X-RAY | 2019 | Xu et al. 2019 |
363 | 6KK7 | Secretin | GLP1 glucagon-like peptide receptor | Human | 3.1 | inactive | PF-06372222 | small molecule | antagonist (negative allosteric modulator) | NA | NA | T4L-IL2 | X-RAY | 2019 | Xu et al. 2019 |
366 | 6PRZ | Rhodopsin | Beta2 adrenergic receptor | Human | 2.8 | inactive | Alprenolol | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
367 | 6PS0 | Rhodopsin | Beta2 adrenergic receptor | Human | 3.4 | inactive | Carazolol | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
368 | 6PS1 | Rhodopsin | Beta2 adrenergic receptor | Human | 3.2 | inactive | Timolol | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
369 | 6PS2 | Rhodopsin | Beta2 adrenergic receptor | Human | 2.4 | inactive | Alprenolol | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
370 | 6PS3 | Rhodopsin | Beta2 adrenergic receptor | Human | 2.5 | inactive | Carvedilol | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
371 | 6PS4 | Rhodopsin | Beta2 adrenergic receptor | Human | 2.6 | inactive | ICI-118551 | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
372 | 6PS5 | Rhodopsin | Beta2 adrenergic receptor | Human | 2.9 | inactive | Propranolol | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
373 | 6PS6 | Rhodopsin | Beta2 adrenergic receptor | Human | 2.7 | inactive | Timolol | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
374 | 6PS7 | Rhodopsin | A2A adenosine receptor | Human | 1.85 | inactive | ZM-241385 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
375 | 6PS8 | Rhodopsin | MT1 melatonin receptor | Human | 3.3 | inactive or minimally activated | 2-Phenylmelatonin | small molecule | agonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2019 | Ishchenko et al. 2019 |
376 | 6NI3 | Rhodopsin | Beta2 adrenergic receptor | Human | 3.8 | activated | BI-167107 | small molecule | agonist | Gs heterotrimer + Beta arrestin 1 (arrestin-2) | Nanobody (bound to G protein) | NA | Electron Microscopy | 2019 | Nguyen et al. 2019 |
377 | 6IQL | Rhodopsin | D4 dopamine receptor | Mouse | 3.5 | inactive | L745870 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Zhou et al. 2019 |
378 | 6PWC | Rhodopsin | NTS1 neurotensin receptor | Human | 4.9 | activated | Neurotensin (9-13) | peptide | agonist | Beta arrestin 1 (arrestin-2) | Fab (bound to arrestin) | NA | Electron Microscopy | 2019 | Yin et al. 2019 |
379 | 6KUW | Rhodopsin | Alpha2C adrenergic receptor | Human | 2.8 | inactive | RS79948 | small molecule | antagonist | NA | NA | PGS-IL3 | X-RAY | 2019 | Chen et al. 2019 |
380 | 6KUX | Rhodopsin | Alpha2A adrenergic receptor | Human | 2.7 | inactive | RS79948 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Qu et al. 2019 |
381 | 6KUY | Rhodopsin | Alpha2A adrenergic receptor | Human | 3.2 | inactive or minimally activated | RES | small molecule | partial agonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Qu et al. 2019 |
382 | 6OL9 | Rhodopsin | M5 muscarinic receptor | Human | 2.54 | inactive | Tiotropium | small molecule | inverse agonist | NA | NA | T4L-IL3 | X-RAY | 2019 | Vuckovic et al. 2019 |
383 | 6RZ6 | Rhodopsin | CysLT2 cysteinyl leukotriene receptor | Human | 2.43 | inactive | ONO-2570366 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Gusach et al. 2019 |
384 | 6RZ7 | Rhodopsin | CysLT2 cysteinyl leukotriene receptor | Human | 2.43 | inactive | ONO-2570366 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Gusach et al. 2019 |
385 | 6RZ8 | Rhodopsin | CysLT2 cysteinyl leukotriene receptor | Human | 2.7 | inactive | ONO-2080365 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Gusach et al. 2019 |
386 | 6RZ9 | Rhodopsin | CysLT2 cysteinyl leukotriene receptor | Human | 2.73 | inactive | ONO-2770372 | small molecule | antagonist | NA | NA | BRIL-IL3 | X-RAY | 2019 | Gusach et al. 2019 |
387 | 6PT2 | Rhodopsin | Delta opioid receptor | Human | 2.8 | activated | KGCHM07 | peptide | agonist | NA | NA | BRIL-NT | X-RAY | 2019 | Claff et al. 2019 |
388 | 6PT3 | Rhodopsin | Delta opioid receptor | Human | 3.3 | activated | DPI-287 | small molecule | agonist | NA | NA | BRIL-NT | X-RAY | 2019 | Claff et al. 2019 |
389 | 6TO7 | Rhodopsin | OX1 orexin receptor | Human | 2.26 | inactive | Suvorexant | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
390 | 6TOD | Rhodopsin | OX1 orexin receptor | Human | 2.11 | inactive | EMPA | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
391 | 6TP3 | Rhodopsin | OX1 orexin receptor | Human | 3.04 | inactive | Daridorexant | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
392 | 6TP4 | Rhodopsin | OX1 orexin receptor | Human | 3.01 | inactive | ACT-462206 | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
393 | 6TP6 | Rhodopsin | OX1 orexin receptor | Human | 2.34 | inactive | Filorexant | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
394 | 6TPG | Rhodopsin | OX2 orexin receptor | Human | 2.74 | inactive | EMPA | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2020 | Rappas et al. 2020 |
395 | 6TPJ | Rhodopsin | OX2 orexin receptor | Human | 2.74 | inactive | Suvorexant | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2020 | Rappas et al. 2020 |
396 | 6TPN | Rhodopsin | OX2 orexin receptor | Human | 2.61 | inactive | HTL6641 | small molecule | antagonist | NA | NA | Glycogen synthase-IL3 | X-RAY | 2020 | Rappas et al. 2020 |
397 | 6TQ4 | Rhodopsin | OX1 orexin receptor | Human | 2.3 | inactive | Comp. 16 | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
398 | 6TQ6 | Rhodopsin | OX1 orexin receptor | Human | 2.55 | inactive | Comp. 14 | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
399 | 6TQ7 | Rhodopsin | OX1 orexin receptor | Human | 2.66 | inactive | SB-334867 | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
400 | 6TQ9 | Rhodopsin | OX1 orexin receptor | Human | 2.65 | inactive | SB-408124 | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
401 | 6JOD | Rhodopsin | AT2 angiotensin II type 2 receptor | Human | 3.2 | activated | Angiotensin II | peptide | agonist | NA | Fab (extracellular) | BRIL-NT | X-RAY | 2020 | Asada et al. 2020 |
402 | 6TOS | Rhodopsin | OX1 orexin receptor | Human | 2.13 | inactive | GSK1059865 | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
403 | 6TOT | Rhodopsin | OX1 orexin receptor | Human | 2.22 | inactive | Lemborexant | small molecule | antagonist | NA | NA | NA | X-RAY | 2020 | Rappas et al. 2020 |
404 | 6KNM | Rhodopsin | Apelin receptor | Human | 3.2 | inactive | JN241 | protein (single domain antibody) | antagonist | NA | Single domain antibody JN241 (extracelllar) | Rubredoxin-IL3 | X-RAY | 2020 | Ma et al. 2020 |
405 | 6P9X | Secretin | CRF1 corticotropin-releasing factor receptor | Human | 2.91 | activated | CRF1 | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2020 | LIang et al. 2020 |
406 | 6P9Y | Secretin | PAC1 receptor | Human | 3.01 | activated | PACAP-38 | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2020 | LIang et al. 2020 |
407 | 6PB0 | Secretin | CRF1 corticotropin-releasing factor receptor | Human | 3.0 | activated | Urocortin-1 | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2020 | Ma et al. 2020 |
408 | 6PB1 | Secretin | CRF2 corticotropin-releasing factor receptor | Human | 2.8 | activated | Urocortin-1 | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2020 | Ma et al. 2020 |
409 | 6KPC | Rhodopsin | CB2 cannabinoid receptor | Human | 3.2 | inactive or minimally activated | AM12033 | small molecule | agonist | NA | NA | T4L-IL3 | X-RAY | 2020 | Li et al. 2020 |
410 | 6KPF | Rhodopsin | CB2 cannabinoid receptor | Human | 2.9 | activated | AM12033 | small molecule | agonist | Gi heterotrimer | ScFv (bound to G protein) | NA | Electron Microscopy | 2020 | Li et al. 2020 |
411 | 6KPG | Rhodopsin | CB1 cannabinoid receptor | Human | 3.0 | activated | AM12033 | small molecule | agonist | Gi heterotrimer | ScFv (bound to G protein) | NA | Electron Microscopy | 2020 | Hua et al. 2020 |
412 | 6KR8 | Rhodopsin | Beta2 adrenergic receptor | Human | 0.0 | inactive | Formoterol (not visible) | small molecule | agonist | NA | NA | NA | NMR | 2020 | Imai et al. 2020 |
413 | 6LRY | Rhodopsin | ETB endothelin receptor | Human | 3.0 | inactive or minimally activated | Sarafotoxin S6B | peptide | agonist | NA | NA | T4L-IL3 | X-RAY | 2020 | Izume et al. 2020 |
414 | 6NWE | Rhodopsin | Rhodopsin | Bovine | 2.7 | activated | Beta-octylglucoside | small molecule | NA | Gt peptide | NA | NA | X-RAY | 2020 | Murizumi et al. 2020 |
415 | 6PT0 | Rhodopsin | CB2 cannabinoid receptor | Human | 3.2 | activated | WIN 55212-2 | small molecule | agonist | Gi heterotrimer | ScFv (bound to G protein) | NA | Electron Microscopy | 2020 | Zing et al. 2020 |
416 | 6OS0 | Rhodopsin | AT2 angiotensin II type 2 receptor | Human | 2.9 | activated | Angiotensin II | peptide | agonist | NA | Nanobody (intracellular) | BRIL-IL3 | X-RAY | 2020 | Wingler et al. 2020 |
417 | 6OS1 | Rhodopsin | AT2 angiotensin II type 2 receptor | Human | 2.79 | activated | TRV023 | peptide | agonist (biased, beta-arrestin) | NA | Nanobody (intracellular) | BRIL-IL3 | X-RAY | 2020 | Wingler et al. 2020 |
418 | 6OS2 | Rhodopsin | AT2 angiotensin II type 2 receptor | Human | 2.7 | activated | TRV026 | peptide | agonist (biased, beta-arrestin) | NA | Nanobody (intracellular) | BRIL-IL3 | X-RAY | 2020 | Wingler et al. 2020 |
419 | 6LI0 | Rhodopsin | GPR52 | Human | 2.2 | inactive or minimally activated | C17 | small molecule | agonist (allosteric) | NA | NA | Flavodoxin-IL3 | X-RAY | 2020 | Lin et al. 2020 |
420 | 6LI1 | Rhodopsin | GPR52 | Human | 2.9 | inactive | Unliganded | NA | NA | NA | NA | Flavodoxin-IL3 | X-RAY | 2020 | Lin et al. 2020 |
421 | 6LI2 | Rhodopsin | GPR52 | Human | 2.8 | inactive | Unliganded | NA | NA | NA | NA | Rubredoxin-IL3 | X-RAY | 2020 | Lin et al. 2020 |
422 | 6LI3 | Rhodopsin | GPR52 | Human | 3.32 | activated | NA | NA | NA | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2020 | Lin et al. 2020 |
423 | 6OMM | Rhodopsin | FPR2/ALX | Human | 3.17 | activated | WKYMVm | peptide | agonist | Gi heterotrimer | ScFv (bound to G protein) | NA | Electron Microscopy | 2020 | Zhuang et al. 2020 |
424 | 6LPB | Secretin | PAC1 receptor | Human | 3.9 | activated | PACAP-38 | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2020 | Kobayashi et al. 2020 |
425 | 6KP6 | Rhodopsin | M4 muscarinic receptor | Human | 3.0 | inactive | NA | NA | NA | NA | NA | Glycogen synthase-IL3 | X-RAY | 2020 | Wang et al. 2020 |
426 | 6LUQ | Rhodopsin | D2 dopamine receptor | Human | 3.1 | inactive | Haloperidol | small molecule | antagonist | NA | NA | T4L-IL3 | X-RAY | 2020 | Fan et al. 2020 |
427 | 6M1I | Secretin | PAC1 receptor | Human | 3.5 | activated | PACAP-38 | peptide | agonist | Gs heterotrimer | Nanobody (bound to G protein) | NA | Electron Microscopy | 2020 | Wang et al. 2020 |
Acknowledgement. The preparation and maintenance of this webpage is supported by the National Institute of General Medical Sciences (NIGMS) of the National Institutes of Health (NIH) under award number R15GM119084. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of NIGMS or NIH.
Disclaimer. The content of this website expresses solely the views of the writer, which should not be construed as the views of any present or past employer.